Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure
Sponsor: Bayer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Bayer
Other Congestive Heart Failure trials with similar outcome
This PHASE2 trial investigates Congestive Heart Failure and is currently terminated or withdrawn. Bayer leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Nauheim, Germany , Bad Oeynhausen, Germany , Barcelona, Spain , Barnet, United Kingdom , Belgrade, Serbia , Bergamo, Italy , Berlin, Germany , Bologna, Italy , Bonn, Germany , Boston, United States and 57 more locations